Screener
Haemonetics HAE MedSurg — Cost of goods sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Research and development | 6,378 | 6,816 |
| Apheresis operating income | $56,545 | $59,175 |
| MedSurg | ||
| Cost of goods sold | $50,368 | $50,216 |
| Selling, general and administrative | 65,160 | 62,323 |
| Research and development | 9,820 | 8,742 |
| MedSurg operating income | $22,714 | $18,377 |
| Corporate and unallocated expenses |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's medsurg — cost of goods sold?
- Haemonetics (HAE) reported medsurg — cost of goods sold of $50.37M in Q2 2026.
- What does medsurg — cost of goods sold mean?
- Includes the direct costs attributable to the production and delivery of products sold within the MedSurg segment, such as raw materials, labor, and manufacturing overhead. It is a key metric for evaluating the segment's gross margin and manufacturing efficiency.
Ask your AI about Haemonetics's medsurg — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude